Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential expression of immune checkpoint VISTA in inflammatory skin diseases.

The Journal of investigative dermatology·2026
Same author

Dysregulated sphingolipid metabolismdrives pancreatic carcinogenesis through plasma membrane Kras enrichment.

Gut·2026
Same author

CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma.

Translational lung cancer research·2026
Same author

Outcomes of PTCY-Based Haploidentical Transplants and Donor Factors Affecting Outcomes: A 12-year Experience from India.

Blood cell therapy·2026
Same author

Lymphomatosis Cerebri Presenting as Steroid-Refractory Demyelinating Disease: A Diagnostic Challenge.

Cureus·2026
Same author

Reduced levels of ITGB1 cause activation of p38MAPK-ERK-LYN axis of BCR::ABL1 signaling despite inactivation of the oncoprotein by imatinib - novel resistance mechanism in blast crisis of chronic myeloid leukemia unraveled.

Cell communication and signaling : CCS·2026

Related Experiment Video

Updated: May 12, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K

Implementation of a CAR-T cell therapy program in India.

Hema Hotchandani1, Manju Sengar1, Alok Shetty1

  • 1Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.

Expert Review of Anticancer Therapy
|May 8, 2025
PubMed
Summary

Indigenous CAR-T cell therapy in India offers hope for blood cancer patients, but challenges in manufacturing, cost, and logistics persist. Strategies are needed to improve accessibility and tailor treatments for better outcomes.

Keywords:
CAR-T cellacute lymphoblastic leukemiachallengeschimeric antigen receptorhematological malignanciesimmunotherapynon-Hodgkin’s lymphomaopportunities

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

378
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.1K

Related Experiment Videos

Last Updated: May 12, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

378
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.1K

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized hematological malignancy treatment, offering curative potential for relapsed/refractory cases.
  • India faces significant challenges in implementing CAR-T cell therapy due to a high burden of hematological malignancies and existing healthcare disparities.

Purpose of the Study:

  • To emphasize optimized patient selection and apheresis slot management for maximizing CAR-T cell therapy benefits.
  • To explore strategies for enhancing CAR-T cell efficacy, accessibility, and affordability in India.
  • To discuss technical and socioeconomic challenges in CAR-T cell development within the Indian context.

Main Methods:

  • Review of current CAR-T cell therapy implementation in India.
  • Analysis of cost-reduction strategies through indigenous development.
  • Exploration of bridging therapies, antibody-based approaches, and combination therapies.

Main Results:

  • Indigenous CAR-T cell development has substantially reduced costs, but manufacturing capacity, high costs, and logistical issues remain barriers.
  • Optimized patient selection and apheresis slot triaging are crucial for maximizing therapeutic benefits.
  • Leveraging India's biotechnology sector and exploring novel combinations present opportunities for cost-efficient production and enhanced efficacy.

Conclusions:

  • Addressing technical and socioeconomic challenges is vital for widespread CAR-T cell accessibility and affordability in India.
  • Tailoring CAR-T cell protocols to the local population through ongoing research is essential.
  • Future advancements including NK cell therapy, TCR-based approaches, and multi-antigen targeting hold promise for improved therapeutic outcomes.